The role of HER2 in human carcinogenesis was first established when it was reported that about 20–30% of breast carcinomas display HER2 amplifications and HER2 protein overexpression, which was associated with aggressive biological behavior and poor patient outcomes [31]. This evidence concerns the gene ERBB2 and breast carcinoma.